|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BRCA1/2 genes with high-penetrance are tumor suppressor and tumor susceptibility genes that play important roles in the homologous recombination mechanism in DNA repair and increase breast cancer risk.
|
31563594 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, we interbred mice expressing the CRE-recombinase with mice harboring loxP sites at TP53 and BRCA1 (K14-Cre; p53<sup>f/f</sup> Brca1<sup>f/f</sup>) to test the hypothesis that tissue-specific deletion of TP53 and BRCA1 would give rise to tumors reflective of human basal-like breast cancer.
|
30484104 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Cancer therapies using defects in homologous recombination (HR) DNA repair pathway of tumor cells are not yet approved to be applicable in patients with malignancies other than BRCA1/2-mutated tumors.
|
31423128 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Conversely, among patients with non-BRCA-associated cancer types, most carriers of these BRCA1/2 mutation types had evidence for tumour pathogenesis that was independent of mutant BRCA1/2.
|
31292550 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BReast Cancer Associated proteins 1 and 2 (BRCA1, -2) and Partner and Localizer of BRCA2 (PALB2) protein are tumour suppressors linked to a spectrum of malignancies, including breast cancer and Fanconi anemia.
|
31017574 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The concordance rate between tumor BRCA test results and germline <i>BRCA1/2</i> status was 87%, with five cases harboring pathogenic/likely pathogenic somatic-only mutations.
|
31653094 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
|
30940100 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Inhibiting IRIS expression limits TNBC tumor growth and progression through an MSC-induced death of IRIS-silenced/inactivated TNBC cells.
|
31014367 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Given its important role in human health and disease, remarkably little is known about the full-length three-dimensional (3D) molecular architecture of the breast cancer type 1 susceptibility protein (BRCA1), or its mechanisms to engage the tumor suppressor, TP53 (p53).
|
30503669 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A total of 1,195 serum and/or tumor specimens were sequenced for <i>BRCA1/2</i> and damaging mutations in homologous recombination repair (HRR) genes.
|
31216226 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Among 161 patients, stromal TIL (sTIL) density was not significantly associated with HRD status (p=0.107) or tumor <i>BRCA1/2</i> mutation status (p=0.391).
|
31796517 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The data presented here indicate that in the absence of BRCA1 germline mutations, a higher number of driver mutations are required for tumor development and that different defective processes are operating in the tumorigenesis of hereditary and sporadic TNBC in young women.
|
31419696 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
However, recent studies not only identify new functions for BRCA1 and BRCA2 in the regulation of transcription and RNA processing potentially relevant to their tumour suppressive activity, but also suggest that monoallelic BRCA2 gene mutations suffice for carcinogenesis.
|
31337537 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
|
30765603 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
CLDN3 was expressed in 58% of BRCA1-mutated tumors compared to only 7% in BRCA2-mutated tumors (p < 0.001) and 1% in WT tumors (p < 0.001).
|
31307407 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC).
|
31015319 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We assessed mutational profiles and proliferative capacity by covariate-adjusted linear models and identified differentially methylated regions using DMRcate in BRCA1-like hormone-receptor-positive tumors.
|
30683142 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast cancer patients with BRCA1/2-driven tumors may benefit from targeted therapy.
|
30175445 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Iterative mouse modeling and comparative oncogenomics analysis show that MYC-overexpression strongly reshapes the CNA landscape of BRCA1-deficient mammary tumors and identify MCL1 as a collaborating driver in these tumors.
|
30674894 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained <i>EF2K</i> gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer.
|
31432749 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers.
|
31537406 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In mucinous neoplasms; altered BRCA-1 was detected in 25 specimens; 7 of 20 (41%) of benign cystadenomas, 5 of 15 (33%) of borderline neoplasms, 9 of 20 (45%) of primary carcinoma, and 4 of 5 (80%) of the metastatic deposits.
|
30446260 |
2019 |
|
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Here we show that in the BRCA1-A complex structure, ABRAXAS integrates the DNA repair protein RAP80 and provides a high-affinity binding site that sequesters the tumor suppressor BRCA1 away from the break site.
|
31253574 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Interestingly, based on the results of the subgroup analysis, the F352 V polymorphism was associated with the overall risk of neoplasms in BRCA1 mutation carriers but not in BRCA2 mutation carriers.
|
30633899 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A total of 54 (23.3%) ovarian cancer patients were found to harbor BRCA1/2 deleterious mutations, and BRCA1/2 mutations were significantly associated with Hereditary Breast and Ovarian Cancer-related tumors and family history of cancer.
|
30972954 |
2019 |